Inflammation as a therapeutic target in acute ischemic stroke treatment

Current Topics in Medicinal Chemistry

Volumn 9, Issue 14, 2009, Pages 1240-1260

  Tuttolomondo, Antonino ^a   Di Sciacca, Riccardo ^a   Di Raimondo, Domenico ^a   Renda, Chiara ^a   Pinto, Antonio ^a   Licata, Giuseppe ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4 FLUOROPHENYL) 5 (2 METHOXY 4 PYRIMIDINYL) 1 IMIDAZOLYL]CYCLOHEXANOL; ADENOSINE TRIPHOSPHATE; ALPHAMBETA2 INTEGRIN; BATIMASTAT; BETA2 INTEGRIN; C REACTIVE PROTEIN; CD36 ANTIGEN; CD39 ANTIGEN; CRX 102; CYTOKINE; DIPYRIDAMOLE; DIZOCILPINE; EP 80317; ETANERCEPT; GELATINASE INHIBITOR; HEXARELIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; KB R 7785; PLACEBO; PREDNISOLONE; PURINERGIC P2X7 RECEPTOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ROSUVASTATIN; SEMAPIMOD; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; ANTIGEN EXPRESSION; BRAIN INJURY; BRAIN ISCHEMIA; CELL INTERACTION; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DRUG INDUSTRY; DRUG TARGETING; ENDOTHELIUM; EXPERIMENTAL STUDY; GRANULOCYTE; HEART INFARCTION; HUMAN; INFLAMMATION; LEUKOCYTE; LOADING DRUG DOSE; LYMPHOCYTE; MACROPHAGE; MIDDLE CEREBRAL ARTERY OCCLUSION; NERVOUS SYSTEM INFLAMMATION; NEUROLOGIC DISEASE; NONHUMAN; PHENOTYPE; REVIEW; RHEUMATOID ARTHRITIS; STROKE; THROMBOSIS; TRAUMATIC BRAIN INJURY; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BRAIN ISCHEMIA; CYTOKINES; INFLAMMATION; STROKE;

EID: 74249120803     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802609789869619     Document Type: Review

References (164)

1. Wang, Q.; Tang, X.N.; Yenari, M.A. The inflammatory response in stroke. J. Neuroimmunol. 2006, 184, 53-68.
2. Barone, F.C.; Schmidt, D.B.; Hillegass, L.M.;Price, W.J.; White, R.F.; Feuerstein ,G.Z.; Clark, R.K.; Lee, E.V.; Griswold D.E, Sarau, H.M. Reperfusion increases neutrophils and leukotriene B4 receptor binding in rat focal ischemia. Stroke 1992, 23, 1337-1347.
3. Barone, F.C.; Hillegass, L.M.; Price, W.J. White, R.F.; Lee, E.V.; Feuerstein, G.Z.; Sarau, H.M.; Clark, R.K.; Griswold D.E. Polymorphonuclear leukocyte infiltration into cerebral focal ischemic tissue, myeloperoxidase activity assay and histologic verification. J. Neurosci. Res. 1991, 29, 336-345.
4. Barone, F.C. Ischemic stroke intervention requires mixed cellular protection of the penumbra. Curr. Opin. Invest. Drugs 2009, (10), 220-223.
5. Beamer,. N.B.; Coull, B.M.; Clark, W.M.; Hazel, J.S.; Silberger, Dereski, M.O.; Chopp, M.; Knight, R.A.; Garcia, H. Focal cerebral ischemia in the rat, temporal profile of neutrophil responses. Neurosci. Res. Commun. 1992, 11, 179-186
6. Arenillas, J.F.; Alvarez-Sabín, J.; Molina, C.A.; Chacón, P.; Montaner, J.; Rovira, A.; Ibarra, B.; Quintana, M. C-reactive protein predicts further ischemic events in first-ever transient ischemic attack or stroke patients with intracranial large-artery occlusive disease. Stroke 2003, 34(10), 2463-8.
7. Andersson, J.; Johansson, L.; Ladenvall, P.; Wiklund, P.G.; Stegmayr, B.; Jern, C.; Boman, K. C-reactive protein is a determinant of first-ever stroke, prospective nested case-referent study. Cerebrovasc. Dis. 2009, 27(6), 544-51
8. Chen, P.C.; Chien, K.L.; Hsu, H.C.; Su, T.C.; Sung, F.C.; Lee, Y.T. Metabolic syndrome and C-reactive protein in stroke prediction: a prospective study in Taiwan. Metabolism 2009, 58(6), 772-8.
9. Qamirani, E.; Ren, Y.; Kuo, L.; Hein, T.W. C-reactive protein inhibits endothelium-dependent NO-mediated dilation in coronary arterioles by activating p38 kinase and NAD(P)H oxidase. Arterioscler. Thromb. Vasc. Biol. 2005, 25(5), 995-1001.
10. Kuhlmann, C.R.; Librizzi, L.; Closhen, D.; Pflanzner, T.; Lessmann, V.; Pietrzik, C.U.; de Curtis, M.; Luhmann, H.J. Mechanisms of C-reactive protein-induced blood-brain barrier disruption. Stroke 2009, 40(4), 1458-66.
11. Welsh, P.; Barber, M.; Langhorne, P.; Rumley, A.; Lowe, G.D.; Stott, D.J. Associations of inflammatory and haemostatic biomarkers with poor outcome in acute ischaemic stroke. Cerebrovasc. Dis. 2009, 27(3), 247-53.
12. Shantikumar, S.; Grant, P.J.; Catto, A.J.; Bamford, J.M.; Carter, A.M. Elevated C-reactive protein and long-term mortality after ischaemic stroke, relationship with markers of endothelial cell and platelet activation. Stroke 2009, 40(3), 977-9.
13. Ryu, S.R.; Choi, I.S.; Bian, R.X.; Kim, J.H.; Han, J.Y.; Lee, S.G. The effect of C-reactive protein on functional outcome in ischemic stroke patients. Int. J. Neurosci. 2009, 119(3), 336.
14. Idicula, T.T.; Brogger, J.; Naess, H.; Waje-Andreassen, U.; Thomassen, L. Admission C-reactive protein after acute ischemic stroke is associated with stroke severity and mortality, the 'Bergen stroke study'. BMC Neurol. 2009, 9, 18.
15. Renvert, S.; Lindahl, C.; Roos-Jansåker, A.M.; Lessem, J. Short-term effects of an anti-inflammatory treatment on clinical parameters and serum levels of C-reactive protein and proinflammatory cytokines in subjects with periodontitis. J. Periodontol. 2009, 80(6), 892-900.
16. Albert, M.A.; Danielson, E.; Rifai, N.; Ridker, P.M. PRINCE Investigators Effect of statin therapy on C-reactive protein levels, the pravastatin inflammation/CRP evaluation (PRINCE), a randomized trial and cohort study. JAMA 2001, 286(1), 64-70.
17. Gensini, G.F.; Gori, A.M.; Dilaghi, B.; Rostagno, C.; Gaw, A.; Blanco-Colio, L.M.; de Teresa, E.; Egido, J.; Farsang, C.; Leiter, L.A.; Martineau, P.; Nozza, A.; Langer, A. Effect of atorvastatin on circulating hsCRP concentrations: A sub-study of the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study on behalf of the ACTFAST investigators. Int. J. Cardiol. 2009 [Epub ahead of print].
18. Ridker, P.M.; Danielson, E.; Fonseca, F.A.; Genest, J.; Gotto, A.M. Jr, Kastelein, J.J.; Koenig, W.; Libby, P.; Lorenzatti, A.J.; Macfadyen, J.G.; Nordestgaard, B.G.; Shepherd, J.; Willerson, J.T.; Glynn, R.J. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin, a prospective study of the JUPITER trial. JUPITER Trial Study Group. Lancet 2009, 373(9670), 1175-82.
19. Febbraio, M.; Hajjar, D.P.; Silverstein, R.L. CD36, a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J. Clin. Invest. 2001, 108, 785-791.
20. Cho, S.; Szeto, H.H.; Kim, E.; Kim, H.; Tolhurst, A.T.; Pinto, J.T. A novel cell-permeable antioxidant peptide, SS31, attenuates ischemic brain injury by down-regulating CD36. J. Biol. Chem. 2007, 282, 4634-4642.
21. Cho, S.; Park, E.M.; Febbraio, M.; Anrather, J.; Park, L.; Racchumi, G.; Silverstein, R.L.; Iadecola, C. The class B scavenger receptor CD36 mediates free radical production and tissue injury in cerebral ischemia. J. Neurosci. 2005, 25, 2504-2512.
22. Ziegler, G.; Harhausen, D.; Schepers, C.; Hoffmann, O.; Röhr, C.; Prinz, V.; König, J.; Lehrach, H.; Nietfeld, W.; Trendelenburg, G. TLR2 has a detrimental role in mouse transient focal cerebral ischemia. Biochem. Biophys. Res. Commun. 2007, 359, 574-579.
23. Hoebe, K.; Georgel, P.; Rutschmann, S.; Du, X.; Mudd, S.; Crozat, K.; Sovath, S.; Shamel, L.; Hartung, T.; Zähringer. U.; Beutler, B CD36 is a sensor of diacylglycerides. Nature 2005, 433, 523-527.
24. Febbraio, M.; Podrez, E.A.; Smith, J.D.; Hajjar, D.P.; Hazen, S.L.; Hoff, H.F.; Sharma, K.; Silverstein, R.L. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J. Clin. Invest. 2000, 105, 1049-10.
25. El Khoury, J.B.; Moore, K.J.; Means, T.K.; Leung, J.; Terada, K.; Toft, M.; Freeman, M.W.; Luster, A.D. CD36 mediates the innate host response to beta-amyloid. J. Exp. Med. 2003, 197, 1657-1666.
26. Su, X.; Maguire-Zeiss, K.A.; Giuliano, R.; Prifti, L.; Venkatesh, K.; Federoff, H.J. Synuclein activates microglia in a model of Parkinson's disease. Neurobiol. Aging 2007, 1690-1701.
27. Demers, A.; McNicoll, N.; Febbraio, M.; Servant, M.; Marleau, S.; Silverstein, R.; Ong, H. Identification of the growth hormone-releasing peptide binding site in CD36, a photoaffinity cross-linking study. Biochem. J. 2004, 382, 417-424.
28. Cho, S.; Park, E.M.; Febbraio, M.; Anrather, J.; Park, L.; Racchumi, G.; Silverstein, R.L.; Iadecola, C. The class B scavenger receptor CD36 mediates free radical production and tissue injury in cerebral ischemia. J. Neurosci. 2005, 25(10), 2504-12.
29. Minami, M.; Kuraishi, Y.; Yabuuchi, K.; Yamazaki, K.; Satoh, M. Induction of interleukin-lb mRNA in rat brain after transient forebrain ischaemia. J. Neurochem. 1992, 58, 390-392.
30. Buttini, H.; Sauter, M.; Boddeke, A. Induction of interleukin-1 beta mRNA after focal cerebral ischaemia in the rat. Mol. Brain Res. 1994, 23(1-2), 126-34.
31. Liu, T.; McDonnell, P.C.; Young, P.R.; White, R.F.; Siren, A.L.; Hallenbeck, J.M.; Barone, F.C.; Feuerstein, G.Z. Interleukin-1 expression in ischemic rat cortex. Stroke, 1993, 24, 1746- 1752.
32. Liu, T.; Young P.R.; McDonnell P.C.; White R.F.; Barone F.C.; Feuerstein, G.Z. Cytokine-induced neutrophil chemoattractant mRNA expressed in cerebral hernia. Neurosci. Lett. 1993, 164, 125-128.
33. Liu, T.; Clark, R.K.; McConnell, P.C.; Young, P.R.; White, R.F.; Barone, F.C.; Wong, D.; Dorovini-Zis, K. Upregulation of intercellular adhesion molecules-l (ICAM-1) expression in primary cultures of human microvessel endothelial cells by cytokines and lipopolysaccharide. J. Neuroimmunol. 1992, 39, 1l-21.
34. Palladino, M.A.; Bahjat, F.R.; Theodorakis, E.A.; Moldawer, L.L. Anti-TNF-alpha therapies, the next generation. Nat. Rev. Drug Discov. 2003, 2(9), 736-4.
35. Tarkowski, E.; Rosengren, L.; Blomstrand, C.; Wikkelda, C.; Jensen, C.; Ekholm, S.; Tarkowski, A. Early intrathecal production of interleukin-6 predicts the size of brain lesion in stroke. Stroke 1995, 26, 1393-1398.
36. Matbiesen, T.; Anderson, B.; Loftenius, A.; von Holst, H. Increased interleukin-6 levels in cerebrospinal fluid foilowing subarachnoid hemorrhage. J. Neurosurg. 1993, 78, 562-567.
37. McClain, C.J.; Cohen, D.; Phyllips. R.; Ott, L. and Young, B. Increased plasma and ventricular interleukm-6 levels in head injured patients. J. Lab. Clin. Med. 1991, 118, 225-230.
38. Liu, T.; Clark, R.K.; McDonnell, P.C.; Young, P.R.; White, R.F.; Barone, F.C.; Feuerstein, G.Z. Tumor necrosis factor-alpha expression in ischemic neurons. Stroke 1994, 25(7), 1481-8.
39. Rosenberg, G.A.; Estrada, E.Y.; Dencoff, J.E. Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke 1998, 29(10), 2189-95.
40. Robertson, J.; Beaulieu, J.M.; Doroudchi, M.M.; Durham, H.D.; Julien, J.P.; Mushynski, W.E. Apoptotic death of neurons exhibiting peripherin aggregates is mediated by the proinflammatory cytokine tumor necrosis factor-alpha. J. Cell Biol. 2001, 155(2), 217-26.
41. Martin-Villalba, A.; Hahne, M.; Kleber, S.; Vogel, J.; Falk, W.; Schenkel, J.; Krammer, P.H. Therapeutic neutralization of CD95-ligand and TNF attenuates brain damage in stroke. Cell Death Differ. 2001, 8(7), 679-86.
42. Nawashiro, H.; Tasaki, K.; Ruetzler, C.A.; Hallenbeck, J.M. TNF-alpha pretreatment induces protective effects against focal cerebral ischemia in mice. J. Cereb. Blood Flow Metab. 1997, 17(5), 483-90.
43. Arend, W.P.; Malyak, M.; Guthridge, C.J.; Gabay, C. Interleukin-1 receptor antagonist, role in biology. Annu. Rev. Immunol. 1998, 16, 27-55.
44. Zhang, W.; Smith, C.; Howlett, C.; Stanimirovic, D. Inflammatory activation of human brain endothelial cells by hypoxic astrocytes in vitro is mediated by IL-1beta. J. Cereb. Blood Flow Metab. 2000, 20(6), 967-78.
45. Nomura, Y.; Fujii, F.; Sato, C.; Nemoto, M.; Tamura, M. Exchange transfusion with fluorocarbon for studying synaptically evoked optical signal in rat cortex. Brain Res. Brain Res. Protoc. 2000, 5(1), 10-5.
46. Orzyłowska, O.; Oderfeld-Nowak, B.; Zaremba, M.; Januszewski, S.; Mossakowski, M. Prolonged and concomitant induction of astroglial immunoreactivity of interleukin-1beta and interleukin-6 in the rat hippocampus after transient global ischemia. Neurosci. Lett. 1999, 263(1), 72-6.
47. Tarkowski, E.; Rosengren, L.; Blomstrand, C.; Wikkelsö, C.; Jensen, C.; Ekholm, S.; Tarkowski, A. Intrathecal release of proand anti-inflammatory cytokines during stroke. Clin. Exp. Immunol. 1997, 110(3), 492-9.
48. Kostulas, N.; Kivisäkk, P.; Huang, Y.; Matusevicius, D.; Kostulas, V.; Link, H. Ischemic stroke is associated with a systemic increase of blood mononuclear cells expressing interleukin-8 mRNA. Stroke 1998, 29(2), 462-6.
49. Vila, N.; Filella, X.; Deulofeu, R.; Ascaso, C.; Abellana, R.; Chamorro, A. Cytokine-induced inflammation and long-term stroke functional outcome. J. Neurol. Sci. 1999, 162(2), 185-8.
50. Smith, C.J.; Emsley, H.C.; Vail, A.; Georgiou, R.F.; Smith, C.J.; Emsley, H.C.; Vail, A. .; Rothwell, N.J.; Tyrrell, P.J.; Hopkins, S.J.; Variability of the systemic acute phase response after ischemic stroke. J. Neurol. Sci. 2006, 251, 77-81.
51. Hallenbeck, J.M. The many faces of tumor necrosis factor in stroke. Nat. Med. 2002, 8, 1363-1368.
52. Fassbender, K.; Rossol, S.; Kammer, T.; Daffertshofer, M.; Wirth, S.; Dollman, M.; Hennerici, M.Proinflammatory cytokines in serum of patients with acute cerebral ischemia, kinetics of secretion and relation to the extent of brain damage and outcome of disease. J. Neurol. Sci. 1994, 122, 135-139.
53. Beamer, N.B.; Coull, B.M.; Clark, W.M.; Briley, D.P.; Wynn, M.; Sexton, G. Persistent inflammatory response in stroke survivors. Neurology 1997, 50, 1722-1728.
54. Tarkowski, E.; Rosengren, L.; Blomstrand, C.; Jensen, C.; Ekholm, S.; Tarkowski, A. Intrathecal expression of proteins regulating apoptosis in acute stroke. Stroke 1999, 30(2), 321-327.
55. Vila, N.; Castillo, J.; Davalos, A.; Chamorro, A. Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke 2000, 31, 2325-2329.
56. Frenkel, D.; Huang, Z.; Maron, R.; Koldzic, D.N.; Moskowitz, M.A.; Weiner, H.L. Neuroprotection by IL-10-producing MOG CD4+ T cells following ischemic stroke. J. Neurol. Sci. 2005, 233, 125-132.
57. Morita, Y.; Takizawa, S.; Kamiguchi, H.; Uesugi, T.; Kawada, H.; Takagi, S. Administration of hematopoietic cytokines increases the expression of anti-inflammatory cytokine (IL-10) mRNA in the subacute phase after stroke. Neurosci. Res. 2007, 58, 356-360.
58. Kes, V.B.; Simundic, A.M.; Nikolac, N.; Topic, E.; Demarin, V. Pro-inflammatory and anti-inflammatory cytokines in acute ischemic stroke and their relation to early neurological deficit and stroke out come. Clin. Biochem. 2008, 41, 1330-1334.
59. Licata, G.; Tuttolomondo, A.; Corrao, S.; Di Raimondo, D.; Fernandez, P.; Caruso, C.; Avellone, G.; Pinto, A. Immunoinflammatory activation during the acute phase of lacunar and non-lacunar ischemic stroke, association with time of onset and diabetic state Int. J. Immunopathol. Pharmacol. 2006, 19(3), 639-46.
60. Licata, G.; Tuttolomondo, A.; Raimondo, D.D.; Corrao, S.; Sciacca, R.D.; Pinto, A. Immuno-inflammatory activation in acute cardio-embolic strokes in comparison with other subtypes of ischaemic stroke. Thromb. Haemost. 2009, 101(5), 929-37.
61. Adams, H.P.; Bendixen, B.H.; Kappelle, J.; Biller, J.; Love, B.; Gordon, M.D.; Marsh, E.E. and the TOAST Investigators. Classification of subtype of acute ischemic stroke. Stroke 1993, e24, 358.
62. Selvarajah, J.R.; Glaves, M.; Wainwright, J.; Jha, A.; Vail, A.; Tyrrell, P.J. Classification of minor stroke, intra-and inter observer reliability. Cerebrovasc. Dis. 2009, 27(3), 209-14.
63. Clark, W.M.; Zivin, J.A. Antileukocyte adhesion therapy, preclinical trials and combination therapy. Neurology 1997, 49(suppl 4), S32-S38.
64. Spera, P.A.; Ellison, J.A.; Feuerstein, G.Z.; Barone, F.C. IL-10 reduces rat brain injury following focal stroke. Neurosci. Lett. 1998, 251, 189-192.
65. Ooboshi, H.; Ibayashi, S.; Kitazono, T.; Yao, H.; Fujishima, M.; Iida, M. Postischemic gene transfer of IL-10 protects against focal ischemia. Stroke 2002, 33, 346.
66. Vila, N.; Castillo, J.; Dávalos, A.; Esteve, A.; Planas, A.M.; Chamorro, A. Levels of anti-inflammatory cytokines and neurological worsening in acute ischemic stroke. Stroke 2003, 34(3), 671-5.
67. Dinarello, C.A. Biologic basis for interleukin-1 in disease. Blood 1996, 87(6), 2095-147.
68. Dinarello, C.A. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int. Rev. Immunol. 1998, 16(5-6), 457-99.
69. Dinarello, C.A. Interleukin-1. Cytokine Growth Factor Rev. 1997, 8(4), 253-65.
70. Fan, L.; Young, P.R.; Barone, F.C.; Feuerstein, G.Z.; Smith, D.H.; McIntosh, T.K. Experimental brain injury induces expression of interleukin-1 beta mRNA in the rat brain. Brain Res. Mol. Brain Res. 1995, 30(1), 125-30.
71. Szaflarski, J.; Burtrum, D.; Silverstein, F.S. Cerebral hypoxiaischemia stimulates cytokine gene expression in perinatal rats. Stroke. 1995, 26(6), 1093-100.
72. Rothwell, N.J.; Luheshi, G.N. Interleukin 1 in the brain, biology, pathology and therapeutic target. Trends Neurosci. 2000, 23(12), 618-25
73. Stroemer, R.P.; Rothwell, N.J. Cortical protection by localized striatal injection of IL-1ra following cerebral ischemia in the rat. J. Cereb. Blood Flow Metab. 1997, 17(6), 597-604.
74. Betz, A.L.; Yang, G.Y.; Davidson, B.L. Attenuation of stroke size in rats using an adenoviral vector to induce overexpression of interleukin-1 receptor antagonist in brain. J. Cereb. Blood Flow Metab. 1995, 15(4), 547-551.
75. Relton, J.K.; Martin, D.; Thompson, R.C.; Russell, D.A. Peripheral administration of Interleukin-1 Receptor antagonist inhibits brain damage after focal cerebral ischemia in the rat. Exp. Neurol. 1996, 138(2), 206-213.
76. Martin, D.; Chinookoswong, N.; Miller, G. The interleukin-1 receptor antagonist (rhIL-1ra) protects against cerebral infarction in a rat model of hypoxia-ischemia. Exp. Neurol. 1994, 130(2), 362-7.
77. Loddick, S.A.; Rothwell, N.J. Neuroprotective effects of human recombinant interleukin-1 receptor antagonist in focal cerebral ischaemia in the rat. J. Cereb. Blood Flow Metab. 1996, 16(5), 932-934.
78. Stroemer, R.P.; Rothwell, N.J. Exacerbation of ischemic brain damage by localized striatal injection of interleukin-1beta in the rat. J. Cereb. Blood Flow Metab. 1998, 18(8), 833-839.
79. Mulcahy, N.J.; Ross, J.; Rothwell, N.J.; Loddick, S.A. Delayed administration of interleukin-1 receptor antagonist protects against transient cerebral ischaemia in the rat. Br. J. Pharmacol. 2003, 140(3), 471-476.
80. Clark, S.R.; McMahon, C.J.; Gueorguieva, I.; Rowland, M.; Scarth, S.; Georgiou, R.; Tyrrell, P.J.; Hopkins, S.J.; Rothwell, N.J. Interleukin-1 receptor antagonist penetrates human brain at experimentally therapeutic concentrations. J. Cereb Blood Flow Metab. 2008, 28(2), 387-394.
81. Fisher, C.J.; Dhainaut, J.A.; Opal, S.M.; Pribble, J.P.; Balk, R.A.; Slotman, G.J.; Iberti, T.J.; Rackow, E.C.; Greenman, R.L. Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome, results from a randomised, double blind, placebo controlled trial. JAMA 1994, 271, 1836-1843.
82. Nuki, G.; Bresnihan, B.; Bear, M.B.; McCabe, D. Long term safety and maintenance of clinical improvement following treatment with Anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis. Arthritis Rheum. 2002, 46, 2838-2846.
83. Gueorguieva, I.; Clark, S.R.; McMahon, C.J.; Scarth, S.; Rothwell, N.J.; Tyrrell, P.J.; Hopkins, S.J.; Rowland, M. Pharmacokinetic modelling of interleukin-1 receptor antagonist in plasma and cerebrospinal fluid of patients following subarachnoid haemorrhage. Br. J. Clin. Pharmacol. 2008, 65(3), 317-325.
84. Emsley, H.C.; Smith, C.J.; Georgiou, R.F.; Vail, A.; Hopkins, S.J.; Rothwell, N.J.; Tyrrell, P.J. Acute Stroke Investigators. A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J. Neurol. Neurosurg. Psychiatry 2005, 76(10), 1366-1372.
85. Standiford, T.J. Anti-inflammatory cytokines and cytokine antagonists. Curr. Pharm. Des. 2000, 6(6), 633-649.
86. Nawashiro, H.; Martin, D.; Hallenbeck, J.M. Inhibition of tumor necrosis factor and amelioration of brain infarction in mice. J. Cereb. Blood Flow Metab. 1997, 17(2), 229-32.
87. Feuerstein, G.; Wang, X.; Barone, F.C. Cytokines in brain ischemia-the role of TNF alpha. Cell Mol. Neurobiol. 1998, 18(6), 695-701.
88. Yang, G.Y.; Gong, C.; Qin, Z.; Ye, W.; Mao, Y.; Bertz, A.L. Inhibition of TNFalpha attenuates infarct volume and ICAM-1 expression in ischemic mouse brain. Neuroreport. 1998, 9(9), 2131-2134.
89. Meistrell, M.E.; 3rd, Botchkina, G.I.; Wang, H.; Di Santo, E.; Cockroft, K.M.; Bloom, O.; Vishnubhakat, J.M.; Ghezzi, P.; Tracey, K.J. Tumor necrosis factor is a brain damaging cytokine in cerebral ischemia. Shock 1997, 8(5), 341-348.
90. Rosenzweig, H.L.; Minami, M.; Lessov, N.S.; Coste, S.C.; Stevens, S.L.; Henshall, D.C.; Meller, R.; Simon, R.P.; Stenzel-Poore, M.P. Endotoxin preconditioning protects against the cytotoxic effects of TNFalpha after stroke, a novel role for TNFalpha in LPS-ischemic tolerance. J. Cereb. Blood Flow Metab. 2007, 27(10), 1663-16674.
91. Black, R.A.; Rauch, C.T.; Kozlosky, C.J.; Peschon, J.J.; Slack, J.L.; Wolfson, M.F.; Castner, B.J.; Stocking, K.L.; Reddy, P.; Srinivasan, S.; Nelson, N.; Boiani, N.; Schooley, K.A.; Gerhart, M.; Davis, R.; Fitzner, J.N.; Johnson, R.S.; Paxton, R.J.; March, C.J.; Cerretti, D.P. A metalloproteinase disintegrin that releases tumournecrosis factor-alpha from cells. Nature 1997, 385(6618), 729-733.
92. Moss, M.L.; Jin, S.L.; Milla, M.E.; Bickett, D.M.; Burkhart, W.; Carter, H.L.; Chen, W.J.; Clay, W.C.; Didsbury, J.R.; Hassler, D.; Hoffman, C.R.; Kost, T.A.; Lambert, M.H.; Leesnitzer, M.A.; McCauley, P.; McGeehan, G.; Mitchell, J.; Moyer, M.; Pahel, G.; Rocque, W.; Overton, L.K.; Schoenen, F.; Seaton, T.; Su, J.L.; Becherer, J.D. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 1997, 385(6618), 733-736.
93. Mohler, K.M.; Sleath, P.R.; Fitzner, J.N.; Cerretti, D.P.; Alderson, M.; Kerwar, S.S.; Torrance, D.S.; Otten-Evans, C.; Greenstreet, T.; Weerawarna, K. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 1994, 370(6486), 218-220.
94. Gearing, A.J.; Beckett, P.; Christodoulou, M.; Churchill, M.; Clements, J.; Davidson, A.H.; Drummond, A.H.; Galloway, W.A.; Gilbert, R.; Gordon, J.L. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature 1994, 370(6490), 555-557.
95. Moro, M.A.; Hurtado, O.; Cárdenas, A.; Romera, C.; Madrigal, J.L.; Fernández-Tomé, P.; Leza, J.C.; Lorenzo, P. Lizasoain Expression and function of tumour necrosis factor-alpha-converting enzyme in the central nervous system. Neurosignals 2003, 12(2), 53-58.
96. Skovronsky, D.M.; Fath, S.; Lee, V.M.; Milla, M.E. Neuronal localization of the TNFalpha converting enzyme (TACE) in brain tissue and its correlation to amyloid plaques. J. Neurobiol. 2001, 49(1), 40-6.
97. Goddard, D.R.; Bunning, R.A.; Woodroofe, M.N. Astrocyte and endothelial cell expression of ADAM 17 (TACE) in adult human CNS. Glia 2001, 34(4), 267-271.
98. Hurtado, O.; Lizasoain, I.; Fernández-Tomé, P.; Alvarez-Barrientos, A.; Leza, J.C.; Lorenzo, P. Moro MATACE/ADAM17-TNF-alpha pathway in rat cortical cultures after exposure to oxygen-glucose deprivation or glutamate. J. Cereb. Blood Flow Metab. 2002, 22(5), 576-85.
99. Lee, S.R.; Tsuji, K.; Lee, S.R.; Lo, E.H. Role of matrix metalloproteinases in delayed neuronal damage after transient global cerebral ischemia. J. Neurosci. 2004, 24(3), 671-678.
100. Jiang, X.; Namura, S.; Nagata, I. Matrix metalloproteinase inhibitor KB-R7785, attenuates brain damage resulting from permanent focal cerebral ischemia in mice. Neurosci. Lett. 2001, 305(1), 41-44.
101. Asahi, M.; Asahi, K.; Jung, J.C.; del Zoppo, G.J.; Fini, M.E.; Lo, E.H. Role for matrix metalloproteinase 9 after focal cerebral ischemia, effects of gene knockout and enzyme inhibition with BB-94. J. Cereb. Blood Flow Metab. 2000, 20(12), 1681-1689.
102. Martin, A.; Herr, I.; Jeremias, I.; Hahne, M.; Brandt, R.; Vogel, J.; Schenkel, J.; Herdegen, T.; Debatin, K.M. CD95 ligand (Fas-L/APO-1L) and tumor necrosis factor-related apoptosis-inducing ligand mediate ischemia-induced apoptosis in neurons. J. Neurosci. 1999, 19(10), 3809-3817.
103. Lavine, S.D.; Hofman, F.M.; Zlokovic, B.V. Circulating antibody against tumor necrosis factor-alpha protects rat brain from reperfusion injury. J. Cereb. Blood Flow Metab. 1998, 18(1), 52-58.
104. Martin-Villalba, A.; Herr, I.; Jeremias, I.; Hahne, M.; Brandt, R.; Vogel, J.; Schenkel, J.; Herdegen, T.; Debatin, K.M. CD95 ligand (Fas-L/APO-1L) and tumor necrosis factor-related apoptosis-inducing ligand mediate ischemia-induced apoptosis in neurons. J. Neurosci. 1999, 19 (10), 3809-3817.
105. Tracey, K.J.; Cerami, A. Tumor necrosis factor, an updated review of its biology. Crit. Care Med. 1993, 21(10 Suppl), S415-422.
106. Semmler, J.; Wachtel, H.; Endres, S. The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-alpha production by human mononuclear cells. Int. J. Immunopharmacol. 1993, 15(3), 409-413.
107. Takahashi, I.; Kobayashi, E.; Nakano, H.; Murakata, C.; Saitoh, H.; Suzuki, K.; Tamaoki, T.J. Potent selective inhibition of 7-O-methyl UCN-01 against protein kinase C. Pharmacol. Exp. Ther. 1990, 255(3), 1218-1221.
108. Prabhakar, U.; Lipshutz, D.; Pullen, M.; Turchin, H.; Kassis, S.; Nambi, P. Protein kinase C regulates TNF-alpha production by human monocytes. Eur. Cytokine Netw. 1993, 4(1), 31-37.
109. Lieberman, A.P.; Pitha, P.M.; Shin, M.L. Poly(A) removal is the kinase-regulated step in tumor necrosis factor mRNA decay. J. Biol. Chem. 1992, 267(4), 2123-2126.
110. Kyriakis, J.M.; Avruch, J. Sounding the alarm, protein kinase cascades activated by stress and inflammation. J. Biol. Chem. 1996, 271(40), 24313-6.
111. Kummer, J.L.; Rao, P.K.; Heidenreich, K.A. Apoptosis induced by withdrawal of trophic factors is mediated by p38 mitogen-activated protein kinase. J. Biol. Chem. 1997, 272(33), 20490-4.
112. Barone, F.C.; Parsons, A.A. Therapeutic potential of antiinflammatory drugs in focal stroke. Expert Opin. Investig. Drugs 2000, 9(10), 2281-306
113. Boehm, J.C.; Smietana, J.M.; Sorenson, M.E.; Garigipati, R.S.; Gallagher, T.F.; Sheldrake, P.L.; Bradbeer, J.; Badger, A.M.; Laydon, J.T.; Lee, J.C.; Hillegass, L.M.; Griswold, D.E.; Breton, J.J.; Chabot-Fletcher, M.C.; Adams, J.L. 1-substituted 4-aryl-5-pyridinylimidazoles, a new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency. J. Med. Chem. 1996, 39(20), 3929-3937.
114. Krause, A.J.; Holtmann, H.; Eickemeier, S.; Winzen, R.; Szamel, M.; Resch, K.; Saklatvala Kracht, M.J. Stress-activated protein kinase/Jun N-terminal kinase is required for interleukin (IL)-1-induced IL-6 and IL-8 gene expression in the human epidermal carcinoma cell line KB. Biol. Chem. 1998, 273(37), 23681-23689.
115. Beyaert, R.; Cuenda, A.; Vanden Berghe, W.; Plaisance, S.; Lee, J.C.; Haegeman, G.; Cohen, P.; Fiers, W. The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor. EMBO J. 1996, 15(8), 1914-1923.
116. Adams, J.L.; Boehm, J.C.; Kassis, S.; Gorycki, P.D.; Webb, E.F.; Hall, R.; Sorenson, M.; Lee, J.C.; Ayrton, A.; Griswold, D.E.; Gallagher, T.F. Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes. Bioorg. Med. Chem. Lett. 1998, 8(22), 3111-3116.
117. Barone, F.C.; Feuerstein, G.Z.; White, R.F. Selective inhibition of p38 mitogen activated kinase reduces brain injury and neurological deficits in rat focal stroke models. J. Cereb. Blood Flow Metab. 1999, 19 (Suppl 1), 5613.
118. Schwartz, M.; Moalem, G.; Leibowitz-Amit, R.; Cohen, I.R. Innate and adaptive immune responses can be beneficial for CNS repair. Trends Neurosci. 1999, 22(7), 295-299.
119. Carlos, T.M.; Harlan, J.M. Leukocyte-endothelial adhesion molecules. Blood 1994, 84, 2068-2101.
120. Okada, Y.; Copeland, B.R.; Mori, E.; Tung, M.M.; Thomas, W.S.; del Zoppo, G.J. P-selectin and intercellular adhesion molecule-1 expression after focal brain ischemia and reperfusion. Stroke 1994, 25, 202-211. 29.
121. Jander, S.; Kraemer, M.; Schroeter, M.; Witte, O.W.; Stoll, G. Lymphocytic infiltration and expression of intercellular adhesion molecule-1 in photochemically induced ischemia of the rat cortex. J. Cereb. Blood Flow Metab. 1995, 15, 42-51.
122. Zhang, R.L.; Chopp, M.; Zaloga, C.; Zhang, Z.G.; Jiang, N.; Gautam, S.C.; Tang, W.X.; Tsang, W.; Anderson, D.C.; Manning, A.M. The temporal profiles of ICAM-1 protein and mRNA expression after transient MCA occlusion in the rat. Brain Res. 1995, 682, 182-188.
123. Haring, H.P.; Berg, E.L.; Tsurushita, N.; Tagaya, M.; del Zoppo, G.J. E-selectin appears in nonischemic tissue during experimental focal cerebral ischemia. Stroke 1996, 27, 1386-1391.
124. Zhang, R.L.; Chopp, M.; Zhang, Z.G.; Phillips, M.L.; Rosenbloom, C.L.; Cruz, R.; Manning, A. E-selectin in focal cerebral ischemia and reperfusion in the rat. J. Cereb. Blood Flow Metab. 1996, 16, 1126-1136.
125. Suzuki, H.; Abe, K.; Tojo, S.; Morooka, S.; Kimura, K.; Mizugaki, M.; Itoyama, Y. Expressions of P-selectin- and HSP72-like immunoreactivities in rat brain after transient middle cerebral artery occlusion. Brain Res. 1997, 759, 321-329.
126. Zhang, R.; Chopp, M.; Zhang, Z.; Jiang, N.; Powers, C. The expression of Pand E-selectins in three models of middle cerebral artery occlusion. Brain Res. 1998, 785, 207-214.
127. Hess, D.C.; Zhao, W.; Carroll, J.; McEachin, M.; Buchanan, K. Increased expression of ICAM-1 during reoxygenation in brain endothelial cells. Stroke 1994, 25, 1463-1467.
128. Stanimirovic, D.B.; Wong, J.; Shapiro, A.; Durkin, J.P. Increase in surface expression of ICAM-1, VCAM-1 and E-selectin in human cerebromicrovascular endothelial cells subjected to ischemia-like insults. Acta Neurochir. Suppl. (Wien). 1997, 70, 12-16.
129. Howard, E.F.; Chen, Q.; Cheng, C.; Carroll, J.E.; Hess, D. NF-kappa B is activated and ICAM-1 gene expression is upregulated during reoxygenation of human brain endothelial cells. Neurosci. Lett. 1998, 248, 199-203.
130. Sobel, R.A.; Mitchell, M.E.; Fondren, G. Intercellular adhesion molecule-1 (ICAM-1) in cellular immune reactions in the human central nervous system. Am. J. Pathol. 1990, 136, 1309-1316.
131. Krupinski, J.; Kaluza, J.; Kumar, P.; Kumar, S.; Wang, J.M. Role of angiogenesis in patients with cerebral ischemic stroke. Stroke 1994, 25, 1794-179.
132. Lindsberg, P.J.; Carpen, O.; Paetau, A.; Karjalainen-Lindsberg, M.L.; Kaste, M. Endothelial ICAM-1 expression associated with inflammatory cell response in human ischemic stroke. Circulation 1996, 94, 939-945.
133. Clark, W.M.; Coull, B.M.; Briley, D.P.; Mainolfi, E. and Rotblein, R. Circulating intercellular adhesion molecule-l levels and neutrophil adhesion in stroke. J. Neuroimmunol. 1993, 44, 125-133
134. Grau, A.J.; Buggle, F.; Heindl, S.; Steichen-Wiehn, C.; Banerjee, T.; Maiwald, M.; Rohlfs, M.; Suhr, H.; Fehn, W.; Becher, H. and Hacke, W. Recent infection as a risk factor for cerebrovascular ischemia. Stroke 1995, 26, 373-379.
135. Kim, J.S.; Chopp, M.; Chen, H.; Levine, S.R.; Carey, J.L. and Welch, K.M.A. Adhesive glycoprotein CD 1 la and CD 18 are upregulated in leukocytes from patients with cerebral ischemia. J. Neurol. Sci. 1995, 128, 45-50.
136. DeGraba, T.J. The role of inflammation after acute stroke, utility of pursuing anti-adhesion molecule therapy. Neurology 1998, 51(suppl 3), S62-S68.
137. Schneider, D.; Berrouschot, J.; Brandt, T.; Hacke, W.; Ferbert, A.; Norris, S.H.; Polmar, S.H.; Schafer, E. Safety, pharmacokinetics and biological activity of enlimomab (anti-ICAM-1 antibody), an open-label, dose escalation study in patients hospitalized for acute stroke. Eur. Neurol. 1998, 40, 78-83.
138. Vuorte, J.; Lindsberg, P.J.; Kaste, M.; Meri, S.; Jansson, S.E.; Rothlein, R.; Repo, H. Anti-ICAM-1 monoclonal antibody R6.5 (enlimomab) promotes activation of neutrophils in whole blood. J. Immunol. 1999, 162, 2353-2357.
139. Furuya, K.; Takeda, H.; Azhar, S.; McCarron, R.M.; Chen, Y.; Ruetzler, C.A.; Wolcott, K.M.; DeGraba, T.J.; Rothlein, R.; Hugli, T.E.; del Zoppo, G.J.; Hallenbeck, J.M. Examination of several potential mechanisms for the negative outcome in a clinical stroke trial of enlimomab, a murine anti-human intercellular adhesion molecule-1 antibody, a bedsideto- bench study. Stroke 2001, 32, 2665-2674.
140. Mocco, J.; Choudhri, T.; Huang, J.; Harfeldt, E.; Efros, L.; Klingbeil, C.; Vexler, V.; Hall, W.; Zhang, Y.; Mack, W.; Popilskis, S.; Pinsky, D.J.; Connolly, E.S. Jr. HuEP5C7 as a humanized monoclonal anti-E/P-selectin neurovascular protective strategy in a blinded placebo-controlled trial of nonhuman primate stroke. Circ. Res. 2002, 91(10), 907-914.
141. Romanic, A.M.; White, R.F.; Arleth, A.J.; Ohlstein, E.H.; Barone, F.C. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats, inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke 1998, 29(5), 1020-1030.
142. Montaner, J.; Alvarez-Sabín, J.; Molina, C.; Anglés, A.; Abilleira, S.; Arenillas, J.; González, M.A.; Monasterio, J. Matrix metalloproteinase expression after human cardioembolic stroke, temporal profile and relation to neurological impairment. Stroke 2001, 32(8), 1759-1766.
143. Montaner, J.; Alvarez-Sabín, J.; Molina, C.A.; Anglés, A.; Abilleira, S.; Arenillas, J.; Monasterio, J. Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke 2001, 32(12), 2762-2767.
144. Horstmann, S.; Kalb, P.; Koziol, J.; Gardner, H.; Wagner, S. Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients,
145. Kang, S.S.; Kook, J.H.; Hwang, S.; Park, S.H.; Nam, S.C.; Kim, J.K. Inhibition of matrix metalloproteinase-9 attenuated neural progenitor cell migration after photothrombotic ischemia. Brain Res. 2008, 1228, 20-26.
146. Wang, Y.; Deng, X.L.; Xiao, X.H.; Yuan, B.X. A non-steroidal anti-inflammatory agent provides significant protection during focal ischemic stroke with decreased expression of matrix metalloproteinases. Curr. Neurovasc. Res. 2007, 4(3), 176-183.
147. Caso, J.R.; Pradillo, J.M.; Hurtado, O.; Lorenzo, P.; Moro, M.A.; Lizasoain, I. Toll-like receptor 4 is involved in brain damage and inflammation after experimental stroke. Circulation 2007, 115(12), 1599-1608.
148. Caso, J.R.; Pradillo, J.M.; Hurtado, O.; Leza, J.C.; Moro, M.A.; Lizasoain, I. Toll-like receptor 4 is involved in subacute stress-induced neuroinflammation and in the worsening of experimental stroke. Stroke 2008, 39(4), 1314-1322.
149. Pradillo, J.M.; Fernández-López, D.; García- Yébenes, I.; Sobrado, M.; Hurtado, O.; Moro, M.A.; Lizasoain, I. Toll-like receptor 4 is involved in neuroprotection afforded by ischemic preconditioning. J. Neurochem. 2009, 109(1), 287-294.
150. Lalouschek, W.; Schillinger, M.; Hsieh, K.; Endler, G.; Greisenegger, S.; Marculescu, R.; Lang, W.; Wagner, O.; Cheng, S.; Mannhalter, C. Polymorphisms of the inflammatory system and risk of ischemic cerebrovascular events. Clin. Chem. Lab. Med. 2006, 44(8), 918-923.
151. Ungaro, R.; Fukata, M.; Hsu, D.; Hernandez, Y.; Breglio, K.; Chen, A.; Xu, R.; Sotolongo, J.; Espana, C.; Zaias, J.; Elson, G.; Mayer, L.; Kosco-Vilbois, M.; Abreu, M.T. A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2009, 296(6), G1167-1179.
152. Gelderblom, M.; Leypoldt, F.; Steinbach, K.; Behrens, D.; Choe, C.U.; Siler, D.A.; Arumugam, T.V.; Orthey, E.; Gerloff, C.; Tolosa, E.; Magnus, T. Temporal and spatial dynamics of cerebral immune cell accumulation in stroke. Stroke 2009, 40 (5), 1849-1857.
153. Stoll, G.; Jander, S.; Schroeter, M. Inflammation and glial responses in ischemic brain lesions. Prog. Neurobiol. 1998, 56, 149-171.
154. Kochanek, P.M.; Hallenbeck, J.M. Polymorphonuclear leukocytes and monocytes/macrophages in the pathogenesis of cerebral ischemia and stroke. Stroke 1992, 23, 1367-1379.
155. Akopov, S.E.; Simonian, N.A.; Grigorian, G.S. Dynamics of polymorphonuclear leukocyte accumulation in acute cerebral infarction and their correlation with brain tissue damage. Stroke 1996, 27, 1739-1743.
156. Saleh, A.; Schroeter, M.; Jonkmanns, C.; Hartung, H.P.; Modder, U.; Jander, S. In vivo MRI of brain inflammation in human ischaemic stroke. Brain 2004, 127, 1670-1677. 6.
157. Rausch, M.; Sauter, A.; Frohlich, J.; Neubacher, U.; Radu, E.W.; Rudin, M. Dynamic patterns of USPIO enhancement can be observed in macrophages after ischemic brain damage. Magn. Reson. Med. 2001, 46, 1018-102.
158. Yilmaz, A.; Fuchs, T.; Dietel, B.; Altendorf, R.; Cicha, I.; Stumpf, C.; Schellinger, P.; Blümcke, I.; Schwab, S.; Daniel, W.G.; Garlichs, C.D.; Kollmar, R. Transient decrease in circulating dendritic cell precursors after acute stroke - potential recruitment into the brain. Clin. Sci. (Lond). 2009, [Epub ahead of print].
159. Kleinschnitz, C.; Bendszus, M.; Frank, M.; Solymosi, L.; Toyka, K.V.; Stoll, G. In vivo monitoring of macrophage infiltration in experimental ischemic brain lesions by magnetic resonance imaging. J. Cereb. Blood Flow Metab. 2003, 23(11), 1356-1361.
160. Kim, J.; Kim, D.I.; Lee, S.K.; Kim, D.J.; Lee, J.E.; Ahn, S.K. Imaging of the inflammatory response in reperfusion injury after transient cerebral ischemia in rats, correlation of superparamagnetic iron oxide-enhanced magnetic resonance imaging with histopathology. Acta Radiol. 2008, 49(5), 580-588.
161. Henning, E.C.; Ruetzler, C.A.; Gaudinski, M.R.; Hu, T.C.; Latour, L.L.; Hallenbeck, J.M.; Warach, S. Feridex preloading permits tracking of CNS-resident macrophages after transient middle cerebral artery occlusion. J. Cereb. Blood Flow Metab. 2009, 29(7), 1229-1139.
162. Ishikawa, M.; Cooper, D.; Arumugam, T.V.; Zhang, J.H.; Nanda, A.; Granger, D.N. Platelet-leukocyte-endothelial cell interactions after middle cerebral artery occlusion and reperfusion. J. Cereb. Blood Flow Metab. 2004, 24(8), 907-915.
163. Hyman, M.C.; Petrovic-Djergovic, D.; Visovatti, S.H.; Liao, H.; Yanamadala, S.; Bouïs, D.; Su, E.J.; Lawrence, D.A.; Broekman, M.J.; Marcus, A.J.; Pinsky, D.J. Self-regulation of inflammatory cell trafficking in mice by the leukocyte surface apyrase CD39. J. Clin. Invest. 2009, 119(5), 1136-1149.
164. Guckelberger, O.; Sun, X.F.; Sévigny, J.; Imai, M.; Kaczmarek, E.; Enjyoji, K.; Kruskal, J.B.; Robson, S.C. Beneficial effects of CD39/ecto-nucleoside triphosphate diphosphohydrolase-1 in murine intestinal ischemia-reperfusion injury. Thromb. Haemost. 2004, 91(3), 576-586.